Compare GE Aerospace (GE) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Nuvalent Inc — how do they compare? GE Aerospace trades at $337.31 (market cap $375.97B), while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: GE Aerospace is far larger — about 38.3× Nuvalent Inc's market cap, and GE Aerospace pays a 0.52% dividend while Nuvalent Inc pays none. Which is the better fit depends on your goals.
| GE | NUVL | |
|---|---|---|
Market Cap | $375.97B | $9.81B |
Sector | Industrials | Technology |
52-Week High | $378.68 | $123.96 |
52-Week Low | $259.00 | $72.16 |
Enterprise Value | $385.26B | $8.52B |
Dividend Yield | 0.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE trades at $353.73, up 0.09% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q1 2026 EPS of $1.86 versus $1.60 expected, driven by robust aerospace demand and defense contract wins. Revenue grew to $45.86 billion in 2025, with net income margin improving to 18.98%. Analysts maintain a strong buy consensus with a $402.63 price target, reflecting optimism about order growth and backlog strength.
Outlook remains positive given earnings momentum and strategic investments in MRO and propulsion, though high valuation ratios (P/E 43.94) and debt levels pose risks. The stock offers upside to consensus targets but faces pressure from rising costs and competitive dynamics in aerospace and defense sectors.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
